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Abstract: Direct, solid phase synthesis of an oligonucleotide conjugate of the antibiotic 
drug metronidazole was accomplished by the phosphoramidite method. Removal of 
protecting groups and cleavage from the controlled pore glass (CPG) solid support was 
successful using mild conditions (20% Et3N in pyridine, then conc. NH3 (aq) at rt for 30 
min) whereas standard conditions (conc. NH3 (aq) at 55 °C for 16 h) cleaved the drug. 
Keywords: CPG, conjugate, metronidazole, oligonucleotide, phosphoramidite, solid 
phase. 
 
Introduction 
Nitroimidazoles, notably metronidazole (1), are important for the treatment of a wide range of 
anaerobic bacterial and protozoan infections due their ability to damage and cleave microbial DNA, 
selectively, under oxygen deficient conditions [1-4]. Although resistance to this class of drug is still 
low, there are reports of its increase [5-9], therefore improvements to delivery, targeting, localization 
and mode of action of such nitroimidazoles, would be beneficial [10]. With their ability to position 
within oxygen-deficient tissue, nitroimidazole derivatives have been investigated as chemotherapeutic 
agents and radiosensitizers in the treatment of hypoxic tumours [2,11,12]. Although studies suggest 
that metronidazole and its metabolites cause damage to DNA and mutagenicity in normal human cells, 
the data remain contradictory [13,14]. Solution chemistry has allowed attachment of the nitroimidazole 
ring system to oligopyrrole derivatives of the A.T selective, DNA minor groove binding antibiotic 
distamycin [15,16]. Such nitroimidazole oligopyrrole conjugates show high affinity for DNA but no 
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improvement in radiosensitization over the unconjugated nitroimidazole [17]. Under anaerobic 
conditions, nitroimidazoles cause greatest DNA damage at A.T base pair sites. There is therefore scope 
to deliver nitroimidazoles specifically to such sites by forming conjugates with triplex forming 
oligoucleotides (TFOs) that bind in the major grove of DNA by Hoogsteen hydrogen bonding [18]. By 
using metronidazole as a representative nitroimidazole and dT8 as a model TFO, the feasibility of 
conjugate formation by solid phase synthesis was assessed. 
 
Results and Discussion 
The required phosphoramidite derivative 2, for use in solid phase synthesis, was formed directly by 
reaction of metronidazole (1) with 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite in the 
presence of N,N-diisopropylamine using anhydrous conditions (Equation 1). Although the literature 
indicates a longer reaction time for the phosphitylation of the O3′ hydroxyl group of nucleosides, 
analysis by TLC showed that the reaction was complete after 20 min, reflecting the increased 
reactivity of the primary hydroxyl group of metronidazole over the secondary O3′ hydroxyl group of 
nucleosides [19]. Purification of the metronidazole phosphoramidite 2 was achieved by flash column 
chromatography giving 2 in 89% yield. Analysis of 2 by NMR showed a single peak at 8.0 ppm in the 
proton spectrum corresponding to H4. A single peak at 51.4 ppm in the phosphorus NMR spectrum 
with no accompanying H-phosphonate peaks, typically observed near 0 ppm, confirmed the identity of 
2 and indicated high purity. The stability of 2 was confirmed during prolonged storage at 4 oC and 
subsequent re-analysis by proton NMR. Automated solid phase synthesis of the metronidazole 
oligonucleotide conjugate 3 on controlled pore glass (CPG) was performed using the standard 
phosphoramidite method [20]. 
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Aware of the potential danger to the nitroimidazole ring system that standard conditions for 
removal of the cyanoethyl protecting groups and release of the conjugate from the solid support might 
pose, 3 was divided into two portions. The first portion was subjected to standard 
deprotection/cleavage conditions: conc. NH3 (aq) at 55 °C for 16 h (Scheme 1). Reversed phase (RP) 
HPLC analysis of the crude product (Figure 1, middle trace) showed one major component with a 
retention time (tR) of 11.7 min. The main component was purified by semi-preparative RP HPLC, and 
analysis by negative ion electrospray mass spectrometry (ESMS (-)) gave a molecular weight of 
2494.1 corresponding to 4 with a calculated molecular weight of 2492.4. 
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Scheme 1. 
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Reagents and conditions: (i) conc. NH3 (aq), 55 °C, 16 h; (ii) 20% Et3N in pyridine, 2 h, 
rt; (iii) conc. NH3 (aq), 30 min, rt. 
 
Clearly, the nitroimidazole ring is not compatible with the standard conditions, therefore milder 
conditions for protecting group removal and release of the conjugate from the solid support were then 
applied to the remainder of 3. Thus, 3 was treated firstly with 20% Et3N in pyridine at room 
temperature for 2 h, to remove the cyanoethyl protecting groups, then with conc. NH3 (aq) at room 
temperature for 30 min, to cleave the conjugate from the solid support. RP HPLC analysis of the crude 
product (Figure 1, upper trace) showed one major component with tR 13.1 min and no accompanying 
minor components. ESMS (-) analysis confirmed the structure of the product as the target 
metronidazole oligonucleotide conjugate 5 with the molecular weight found, 2604.2, being within 
0.1% of the calculated value 2603.4. Co-injection of 4 and conjugate 5 (Figure 1, lower trace) show 
the two to be clearly distinguished with 4 eluted before the marginally more lipophilic 5. 
Displacement of the nitroimidazole ring in 3 by ammonia in a SN2 process to form 4 is least likely 
as ammonia is not a strong enough nucleophile and imidazole is too poor a leaving group, despite 
activation by the nitro substituent [21]. When the purified metronidazole conjugate 5 was treated with 
conc. NH3 (aq) at 16 h for 55 °C, and analysed by RP HPLC, no by-products other than 4 were 
observed at the detection wavelength (260 nm). A commercial sample of 2-methyl-5-nitroimidazole 
gave tR 7.8 min under the same RP HPLC analysis conditions. 
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Figure 1. Reversed phase HPLC profiles of the target metronidazole oligonucleotide 
conjugate 5 with retention time 13.1 min (upper trace), aminoethyl oligonucleotide 
conjugate 4 with retention time 11.7 min (middle trace) and a co-injection of both 
conjugates 4 and 5 (lower trace). The vertical axes show milliabsorbance units (mAU) 
and the horizontal axes show retention time. 
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When refluxed with 4-dimethylaminopyridine (DMAP), 2-bromo-4,5-dicyanoimidazole undergoes 
substitution at C2 with concomitant detachment of its N1 methyl group, albeit in low yield (38%) 
(Equation 2), because the 4,5-dicyanoimidazole anion is a better leaving group than a singly activated 
imidazole ring [22]. Formation of 4 from 3 is therefore most likely to be due to fragmentation of the 
nitroimidazole ring. 
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The reactivity of metronidazole (1) towards various nucleophiles is well documented in the 
literature [21,23] but not, as far as we are aware, its reactivity towards aqueous ammonia. The 
literature shows that attack on the nitroimidazole ring system is possible at C2, C4 or C5 but is heavily 
dependant on the other substituents present and the particular nucleophile employed. Use of liquid 
ammonia allows replacement of the methylsulfonyl group with amino at C2 (Equation 3) [23]. When 
sulphur nucleophiles such as cysteine are employed, it is reported that replacement of the 5-nitro group 
occurs in a pH-dependent manner (Equation 4) [24]. Thiol-mediated nitro group displacements are 
known to occur readily in appropriately substituted benzene and other aromatic rings by the classical 
addition/elimination mechanism [25]. By contrast, 1,2-dimethyl-5-nitroimidazole reacts with 
hydroxyl-amine to give the corresponding 4-amino derivative (Equation 5) [26].  
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Metronidazole (1) has been reported to react with hydrazine by attack at C4 to give a separable 
mixture of 1-amino-2,5-dimethyl-1,3,4-triazine, glyoxal dihydrazone and ethanolammonium nitrite 
(Equation 6) with similar reactivity towards hydrazine being observed for 1,2-dimethyl-5-
nitroimidazole [27]. Involvement of a bicyclic intermediate during hydrazine-mediated ring 
fragmentation of 1 is proposed, as near quantitative recovery of 1 was achieved after exposure to neat 
1,1-dimethylhydrazine (28 h, 55 °C). Similarly, 1 was recovered (86%) after exposure to benzylamine 
in THF (17 h, 63 °C) [27].  
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Comparison of the X-ray crystal structure of tinidazole (6) [28] with that of imidazole reveals a 
shortened C3-C4 bond and lengthened C4-C5 bond, perhaps due to a contribution from structure 7 [23]. 
Formation of 4 from 3 is therefore most likely due to fragmentation of the nitroimidazole ring but it is 
not clear which position of nitroimidazole ring, C2, C4 or C5, undergoes initial attack in conc. NH3 
(aq). 
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General applicability of this method for solid phase synthesis of metronidazole conjugates of 
oligonucleotides containing each of the other DNA bases in addition to T is expected because 
commercially available [29] A, C and G phosphoramidites contain formamidine or phenoxyacetyl 
protecting groups, which are cleaveable under the conditions that are compatible with metronidazole. 
Alternatively, the need to use ammonia may be completely avoided by using a solution of lithium 
hydroxide (0.5 M) and triethylamine (3.5 M) in methanol at 70 °C for one hour [30]. These conditions 
are compatible with standard phosphoramidites containing benzoyl protected A and C, and isobutyryl 
protected G bases [30]. 
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Experimental 
General 
1H and 31P-NMR spectra were recorded on a Bruker AC250 spectrometer at 250.1 and 101.3 MHz, 
respectively. Positive chemical shifts are downfield of tetramethylsilane for 1H and downfield of 85% 
(aq) H3PO4 for 31P. Negative ion electrospray mass spectrometric analysis was carried out on Hewlett 
Packard HP 5989B MS Engine apparatus using a HP 59987A API electrospray LC/MS interface. Flash 
column chromatography was performed using Sorbsil C60 silica gel [31]. TLC was performed using 
plastic-backed Kieselgel 60 silica gel plates containing a fluorescent indicator and visualised under 
UV (254 nm). DNA synthesis was performed on a Beckman Oligo 1000 Synthesiser following the 
manufacturer’s protocol [32]. HPLC was carried out on a Hewlett Packard Series 1100 instrument with 
the UV detection wavelength set at 260 nm. Gradient elution was performed on a HPLC Technology 
C18 Reversed Phase Column (250 x 4.6 mm) at a flow rate of 1 mL min-1 where solvent system A was 
mixed 0-40% with solvent system B during 20 min. Solvent system A was composed of 1 M aqueous 
triethylammonium acetate (TEAA, 10%) and MeCN (2%) at pH 7.0, and solvent system B was 
composed of 1 M aqueous TEAA (10%) and MeCN (80%) at pH 7.0.  Semi-preparative purification 
was carried out by dissolving the oligonucleotide in H2O (1.5 mL) and injecting aliquots (typically 0.3 
to 0.5 mL) using a 1 mL injection loop and syringe. All solvent and column conditions were as above, 
except that the UV detection wavelength was at 285 nm. Purified oligonucleotides were desalted using 
Waters’ SepPak columns. 
 
Preparation of 2-(2-methyl-5-nitroimidazoyl)-ethyl-(2-cyanoethyl)-N,N-diisopropyl)-phosphoramidite 
(2) 
2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.37 g, 4.65 mmol) was added to a stirred 
solution of metronidazole (0.53 g, 3.1 mmol) and diisopropylamine (0.31 g, 9.1 mmol) in dry THF (15 
ml) under Ar. After stirring for 1 h at rt the reaction mixture was evaporated under reduced pressure 
and dried under high vacuum. The metronidazole phosphoramidite 2 (1.02 g, 89%) was isolated by 
flash column chromatography (EtOAc) and dried under high vacuum. TLC (EtOAc) Rf 0.38; 1H-NMR 
[(CD3)2SO]: δ 1.03 (12H, m, 4 x CH3 (Pri)), 2.50 (3H, s, 2-CH3), 2.71 (2H, t, J = 5.8 Hz, OCH2CH2Ar), 
3.43 (2H, m, OCH2CH2CN), 3.62 (2H, m, 2 x CHPri2), 3.85 (2H, m, OCH2CH2CN), 4.51 (2H, t, J = 
5.8 Hz, OCH2CH2Ar), 8.04 ppm (1H, s, 4-H (Ar)); 31P-NMR [(CD3)2SO]: δ 51.45 ppm (s). 
 
Preparation of protected, solid supported metronidazole oligonucleotide conjugate 3 
Synthesis of solid supported conjugate 3 was achieved by the standard phosphoramidite method 
[20,32] on a 1000 nM scale using CPG derivatised with dT (28 mg). The metronidazole 
phosphoramidite 2 (0.1 M in MeCN) was used during the final coupling step. The solid CPG support 
was dried using a stream of Ar then divided into two portions for the following deprotection/cleavage 
steps. 
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Preparation of aminoethyl oligonucliotide conjugate 4 
To solid supported conjugate 3 (10 mg) was added conc. NH3 (aq) and the mixture heated in a 
sealed tube at 55 °C during 16 h. The product was purified by semi-preparative HPLC affording 4 (22 
O.D.); RP HPLC: tR 11.7 min; ESMS (-): calculated 2492.4, found 2494.1.  
 
Preparation of metronidazole oligonucleotide conjugate 5 
To the solid supported conjugate 3 (17 mg) was added 20% Et3N in pyridine (1 mL) and the 
mixture was gently swirled at rt for 2 h. The solid support was then washed with MeCN (2 x 1 mL) 
then Et2O (2 x 1 mL) and left to dry in the air. Concentrated NH3 (aq) was then added to the support 3 
and the mixture was then left at rt for 30 min. The product was purified by RP HPLC affording 5 (5 
O.D.); HPLC: tR 13.1 min; ESMS (-): calculated 2603.4, found 2604.2. The HPLC profile of co-
injected 4 and 5 showed two distinct peaks. 
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